Edesa Biotech Ownership
EDSA Stock | USD 2.24 0.19 7.82% |
Shares in Circulation | First Issued 2008-09-30 | Previous Quarter 3.2 M | Current Value 3.3 M | Avarage Shares Outstanding 839 K | Quarterly Volatility 1.1 M |
Some institutional investors establish a significant position in stocks such as Edesa Biotech in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Edesa Biotech, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Edesa |
Edesa Stock Ownership Analysis
About 16.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.87. Edesa Biotech last dividend was issued on the 10th of June 2019. The entity had 1:7 split on the 11th of October 2023. Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada. Edesa Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people. To learn more about Edesa Biotech call MD FRCPC at 289 800 9600 or check out https://www.edesabiotech.com.Besides selling stocks to institutional investors, Edesa Biotech also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Edesa Biotech's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Edesa Biotech's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Edesa Biotech Quarterly Liabilities And Stockholders Equity |
|
Edesa Biotech Insider Trades History
About 9.0% of Edesa Biotech are currently held by insiders. Unlike Edesa Biotech's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Edesa Biotech's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Edesa Biotech's insider trades
Edesa Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Edesa Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Edesa Biotech backward and forwards among themselves. Edesa Biotech's institutional investor refers to the entity that pools money to purchase Edesa Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | |||
Bank Of America Corp | 2024-12-31 | 19.0 | |
Morgan Stanley - Brokerage Accounts | 2024-12-31 | 14.0 | |
Crédit Agricole S.a. | 2024-09-30 | 1.0 | |
Allsquare Wealth Management Llc | 2024-12-31 | 1.0 | |
Northern Trust Investments N A | 2024-12-31 | 0.0 | |
Dimensional Fund Advisors, Inc. | 2024-12-31 | 0.0 | |
Cibc World Markets Inc. | 2024-09-30 | 0.0 | |
Efficient Wealth Management Llc | 2024-12-31 | 0.0 | |
Cm Management, Llc | 2024-12-31 | 110 K | |
Geode Capital Management, Llc | 2024-12-31 | 19.8 K | |
Vanguard Group Inc | 2024-12-31 | 15.9 K |
Edesa Biotech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edesa Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edesa Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Edesa Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Edesa Biotech Outstanding Bonds
Edesa Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Edesa Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Edesa bonds can be classified according to their maturity, which is the date when Edesa Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
MGM Resorts International Corp BondUS552953CD18 | View |
Edesa Biotech Corporate Filings
18th of February 2025 Other Reports | ViewVerify | |
8K | 14th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 20th of December 2024 An amendment to a previously filed Form 10-K | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.